诺普拉赞与兰索普拉在侵蚀性食道炎中的作用 - - 随机对照试验的系统审查和元分析
Saurabh Chandan1, Smit Deliwala2, Babu P Mohan3
1Division of Gastroenterology and Hepatology, Creighton University School of Medicine, Omaha, NE, USA.
概括
与兰索普拉相比,诺普拉赞在侵蚀性食道炎 (EE) 的内镜愈合率更高,特别是在严重病例中. 这两种治疗方法都显示了相似的安全性,为EE管理提供了有效的选择.
科学领域:
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 质子抑制剂 (PPI) 是侵蚀性食道炎 (EE) 的标准药物.
- 沃诺普拉桑是一种与竞争的酸阻断剂,为EE提供了替代治疗方法.
- 这项研究系统地审查了随机对照试验 (RCT),比较vonoprazan与lansoprazole用于EE治疗.
结论:
- 诺普拉赞 (每天服用20毫克一次) 在EE患者的内镜愈合率与兰索普拉佐 (每天服用30毫克一次) 相同或更高,特别是在严重病例中.
- 发现在vonoprazan和lansoprazole的安全性概况是可以比较的.
- 证据的高度确定性 (A级) 支持诺普拉桑作为对EE的有效治疗方法的这些发现.
相关概念视频
Peptic Ulcer Disease IV: Management
113
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
113
Gastroesophageal Reflux Disease II: Clinical Features and Management
116
Gastroesophageal reflux disease, or GERD, is a persistent medical condition that affects many individuals worldwide. Its clinical manifestations can vary greatly, making diagnosis and management challenging for healthcare professionals. The following is a comprehensive overview of the clinical manifestations, assessment, and management strategies for GERD.
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
116
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
472
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
472
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
517
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
517
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
563
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
563
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
507
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
507


